19 June 2013
Keywords: gsk, theravance, report, strong, ics, results, uk
Article | 23 February 2009
UK drug major GlaxoSmithKline and the USA's Theravance have reported positive results from three Phase IIb studies assessing efficacy and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 February 2009
18 June 2013
© 2013 thepharmaletter.com